Learn More About CMT Research
Find a CMTA Center of Excellence
Get Involved with our Youth Program
Participate in a CMTA Event

CMTA News

September is CMT Awareness Month, so let's beat CMT.

Let’s Beat CMT – 2024 CMT Awareness Month

Read More

New Therapeutic Pathways for CMT1B: UPR Activation Research

Exploring New Therapeutic Pathways for CMT1B: UPR Activation

Read More

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

Read More

Actio Bio receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation.

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

Read More

CMTA Partner Applied Therapeutics to Submit NDA for CMT-SORD Treatment

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

Read More

Repurposing Drugs for CMT1A: An Encouraging Approach

Read More

Exploring New Therapeutic Pathways for CMT1B: UPR Activation

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

Repurposing Drugs for CMT1A: An Encouraging Approach

Gene Replacement Therapy in CMT4 Subtypes

Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy

DNA-Based Therapeutics: A Promising Future for CMT2E Treatment

What is CMT?

Living With CMT

CMT doesn’t have to stop you from doing the things you want to do. We have ...

Living with CMT

Researching the Cure

Over $23.5 million invested in STAR research driving our vision of a world without CMT ..

Our Research